Innogenetics Bid Could Give Gen-Probe A Larger Slice Of European Pie
This article was originally published in The Gray Sheet
Executive Summary
Gen-Probe's offer to acquire Belgian molecular assay maker Innogenetics for about $334 million, announced June 3, would nearly double the diagnostics firm's international sales and give it a larger piece of the rapidly expanding European market
You may also be interested in...
Innogenetics Weighs Solvay’s Sweetened Takeover Offer Trumping Gen-Probe
Gen-Probe says it will not increase its offer for Belgian molecular diagnostics firm Innogenetics now that drug maker Solvay has submitted a higher bid, worth $316 million for all of Innogenetics' outstanding shares
Innogenetics Weighs Solvay’s Sweetened Takeover Offer Trumping Gen-Probe
Gen-Probe says it will not increase its offer for Belgian molecular diagnostics firm Innogenetics now that drug maker Solvay has submitted a higher bid, worth $316 million for all of Innogenetics' outstanding shares
Gen-Probe HPV test
San Diego firm launches its Aptima molecular assay for human papillomavirus (HPV) in Europe May 28 upon gaining a CE mark. The assay, which detects 14 high-risk HPV types associated with cervical cancer, runs on Gen-Probe's Tigris and DTS instrument platforms. The firm began a 7,000-patient pivotal trial for U.S. approval of Aptima in March (1"The Gray Sheet" April 7, 2008, In Brief). Qiagen/Digene's Hybrid Capture 2 is the only FDA-approved molecular test for HPV